AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 9205821 — intervention group
Group type: EXPERIMENTAL
Intervention: Single dose of JTP-4819 60 mg
Number of subjects: 28
Study 9205821 — intervention group
Group type: EXPERIMENTAL
Intervention: Single dose of JTP-4819 120 mg
Number of subjects: 28
Study 9205821 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple doses of JTP-4819 60 mg three times daily for 7 days
Number of subjects: 28
Study 9205821 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study 9205821 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple doses of JTP-4819 60 mg
Number of subjects: 28
Study 9205821 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple doses of JTP-4819
Number of subjects: 28
Study 9205821 — intervention group
Group type: EXPERIMENTAL
Intervention: Single dose of JTP-4819
Number of subjects: 28
Study 8202233 — intervention group
Group type: EXPERIMENTAL
Intervention: Autologous cryoprecipitate
Number of subjects: 6
Study 8202233 — intervention group
Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 6
Study 2885827 — intervention group
Group type: EXPERIMENTAL
Intervention: Almitrine-raubasine combination
Number of subjects: 36
Study 2885827 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study 31541704 — intervention group
Group type: EXPERIMENTAL
Intervention: Evaluation of the Perception of Physical Activity (EPPA) questionnaire
Number of subjects: 548
Study 31541704 — intervention group
Group type: EXPERIMENTAL
Intervention: EPPA Beliefs subscale
Number of subjects: 548
Study 29573167 — intervention group
Group type: EXPERIMENTAL
Intervention: Active treatment with transcranial pulsed electromagnetic fields (T-PEMFs), 30 minutes daily for eight consecutive weeks.
Number of subjects: 97
Study 29573167 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment (control group).
Number of subjects: 97
Study 29573167 — intervention group
Group type: EXPERIMENTAL
Intervention: Active treatment with T-PEMFs.
Number of subjects: 97
Study 27194717 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous alanyl-glutamine (0.5 g·kg(‐1)·day(‐1))
Number of subjects: 10
Study 27194717 — intervention group
Group type: COMPARATOR
Intervention: No supplement (control group)
Number of subjects: 10
Study 25635977 — intervention group
Group type: EXPERIMENTAL
Intervention: Telmisartan (40 mg a day)
Number of subjects: 41
Study 24088687 — intervention group
Group type: EXPERIMENTAL
Intervention: Integration of family planning services into HIV clinics
Number of subjects: 5682
Study 24088687 — intervention group
Group type: COMPARATOR
Intervention: Referral to family planning clinics (Control)
Number of subjects: 5682
Study 21120597 — intervention group
Group type: EXPERIMENTAL
Intervention: Media system A (G-IVF (TM) v5 PLUS/ G-1(TM) v5 PLUS)
Number of subjects: 110
Study 21120597 — intervention group
Group type: COMPARATOR
Intervention: Media system B (Universal IVF medium/EmbryoAssist (TM))
Number of subjects: 110
Study 18667327 — intervention group
Group type: EXPERIMENTAL
Intervention: HA-group (blood priming containing FFP and human albumin 20%)
Number of subjects: 20
Study 18667327 — intervention group
Group type: COMPARATOR
Intervention: FFP-group (blood priming with fresh frozen plasma)
Number of subjects: 20
Study 16533195 — intervention group
Group type: EXPERIMENTAL
Intervention: Prolotherapy injections and exercises
Number of subjects: 110
Study 12773728 — intervention group
Group type: EXPERIMENTAL
Intervention: Tobacco specific survey introduction
Number of subjects: 3996
Study 12773728 — intervention group
Group type: COMPARATOR
Intervention: General health survey introduction
Number of subjects: 3996
Study 10822743 — intervention group
Group type: EXPERIMENTAL
Intervention: 2-session recognition of intoxication training program
Number of subjects: 45
Study 10822743 — intervention group
Group type: COMPARATOR
Intervention: Attention-placebo control group
Number of subjects: 45
Study 8863992 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon (IFN) treatment
Number of subjects: 0
Study 8863992 — intervention group
Group type: COMPARATOR
Intervention: Nonresponders
Number of subjects: 0
Study 2072069 — intervention group
Group type: EXPERIMENTAL
Intervention: Breast self examination (BSE) practice
Number of subjects: 1315
Study 2072069 — intervention group
Group type: EXPERIMENTAL
Intervention: Conservative surgery eligibility
Number of subjects: 1315
Study 6191137 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol, 80 mg three times daily
Number of subjects: 8
Study 6191137 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoprolol, 100 mg two times daily
Number of subjects: 8
Study 6191137 — intervention group
Group type: COMPARATOR
Intervention: Control, without concurrent drugs
Number of subjects: 8
Study 30782343 — intervention group
Group type: EXPERIMENTAL
Intervention: Lomustine-temozolomide therapy (100 mg/m2 on day 1 plus temozolomide 100–200 mg/m2 per day on days 2–6 of the 6-week course)
Number of subjects: 141
Study 30782343 — intervention group
Group type: COMPARATOR
Intervention: Standard temozolomide therapy (75 mg/m2 per day concomitant to radiotherapy followed by six courses of temozolomide 150–200 mg/m2 per day on the first 5 days of the 4-week course)
Number of subjects: 141
Study 30782343 — intervention group
Group type: EXPERIMENTAL
Intervention: Lomustine-temozolomide therapy
Number of subjects: 141
Study 30782343 — intervention group
Group type: COMPARATOR
Intervention: Standard temozolomide therapy
Number of subjects: 141
Study 30035339 — intervention group
Group type: EXPERIMENTAL
Intervention: Late mild cognitive impairment (LMCI)
Number of subjects: 79
Study 30035339 — intervention group
Group type: COMPARATOR
Intervention: Early mild cognitive impairment (EMCI)
Number of subjects: 79
Study 27370892 — intervention group
Group type: EXPERIMENTAL
Intervention: Betamethasone 8 mg
Number of subjects: 74
Study 27370892 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 74
Study 24923476 — intervention group
Group type: EXPERIMENTAL
Intervention: Linearity assumption for converting MR signal intensity to gadolinium concentration
Number of subjects: 17
Study 24923476 — intervention group
Group type: COMPARATOR
Intervention: Nonlinear conversion method for converting MR signal intensity to gadolinium concentration
Number of subjects: 17
Study 24923476 — intervention group
Group type: EXPERIMENTAL
Intervention: Model-free parameters using both conversion methods
Number of subjects: 17
Study 24923476 — intervention group
Group type: EXPERIMENTAL
Intervention: Modeled parameters using SPGR equations
Number of subjects: 17
Study 22674586 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclamen europaeum extract
Number of subjects: 29
Study 22674586 — intervention group
Group type: COMPARATOR
Intervention: Placebo spray
Number of subjects: 29
Study 19696051 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard Bridging Technique (SBT)
Number of subjects: 100
Study 19696051 — intervention group
Group type: COMPARATOR
Intervention: Traditional Open Technique (TOT)
Number of subjects: 100
Study 18753091 — intervention group
Group type: EXPERIMENTAL
Intervention: Sufentanil 2.5 microg
Number of subjects: 60
Study 18753091 — intervention group
Group type: EXPERIMENTAL
Intervention: Sufentanil 5 microg
Number of subjects: 60
Study 18753091 — intervention group
Group type: EXPERIMENTAL
Intervention: Sufentanil 7.5 microg
Number of subjects: 60
Study 18753091 — intervention group
Group type: COMPARATOR
Intervention: Bupivacaine only (0 microg sufentanil)
Number of subjects: 60
Study 16471120 — intervention group
Group type: EXPERIMENTAL
Intervention: Predictive model based on clinical data including presence of diabetes mellitus and ECG leads with abnormal Q waves.
Number of subjects: 137
Study 16471120 — intervention group
Group type: EXPERIMENTAL
Intervention: Validation of the predictive model in a separate subset of patients.
Number of subjects: 137
Study 12766388 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal nitroglycerin patches (20 mg/24 h) administered intermittently
Number of subjects: 34
Study 12766388 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal nitroglycerin patches (20 mg/24 h) administered continuously
Number of subjects: 34
Study 12766388 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 34
Study 9831410 — intervention group
Group type: EXPERIMENTAL
Intervention: Ondansetron 8 mg tds
Number of subjects: 0
Study 9831410 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 9831410 — intervention group
Group type: EXPERIMENTAL
Intervention: Ondansetron
Number of subjects: 0
Study 8697930 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma exchange (PE) plus D‐penicillamine (group I)
Number of subjects: 29
Study 8697930 — intervention group
Group type: COMPARATOR
Intervention: D‐penicillamine alone (group II)
Number of subjects: 29
Study 2568970 — intervention group
Group type: EXPERIMENTAL
Intervention: Betamethasone-dixyrazine
Number of subjects: 40
Study 2568970 — intervention group
Group type: COMPARATOR
Intervention: High-dose metoclopramide
Number of subjects: 40
Study 809046 — intervention group
Group type: EXPERIMENTAL
Intervention: Briserin (0.1 mg reserpine, 5 mg clopamide, 0.5 mg dihydroergocristin/per tablet)
Number of subjects: 20
Study 809046 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 809046 — intervention group
Group type: EXPERIMENTAL
Intervention: Briserin
Number of subjects: 20
Study 30930609 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behavior Therapy (CBT) with trauma-focused emotion regulation skills (TARGET)
Number of subjects: 29
Study 30930609 — intervention group
Group type: COMPARATOR
Intervention: Cognitive Behavior Therapy (CBT) without trauma-focused emotion regulation skills
Number of subjects: 29
Study 27513260 — intervention group
Group type: EXPERIMENTAL
Intervention: Monosymptomatic nocturnal enuresis (NE) patients
Number of subjects: 38
Study 27513260 — intervention group
Group type: COMPARATOR
Intervention: Healthy subjects (control group)
Number of subjects: 38
Study 24725369 — intervention group
Group type: EXPERIMENTAL
Intervention: Physiotherapy with whole body vibration
Number of subjects: 49
Study 24725369 — intervention group
Group type: COMPARATOR
Intervention: Physiotherapy alone
Number of subjects: 49
Study 24183127 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine patch (21 mg)
Number of subjects: 119
Study 24183127 — intervention group
Group type: COMPARATOR
Intervention: Placebo patch
Number of subjects: 119
Study 24183127 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 119
Study 20632263 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupivacaine
Number of subjects: 159
Study 20632263 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 159
Study 20632263 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupivacaine (preoperative or postoperative)
Number of subjects: 159
Study 18259100 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous alfacalcidol (mean dose 3.63 +/- 1.71 microg/week)
Number of subjects: 185
Study 18259100 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous alfacalcidol
Number of subjects: 185
Study 16632892 — intervention group
Group type: EXPERIMENTAL
Intervention: Cr-enriched yeast (400 microg Cr/d)
Number of subjects: 36
Study 16632892 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study 14635746 — intervention group
Group type: EXPERIMENTAL
Intervention: Hedrocel implants with autologous cancellous bone graft
Number of subjects: 24
Study 14635746 — intervention group
Group type: EXPERIMENTAL
Intervention: Solid block implant
Number of subjects: 24
Study 14635746 — intervention group
Group type: EXPERIMENTAL
Intervention: Autologous tricortical iliac crest bone graft
Number of subjects: 24
Study 12196612 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based resource guide for service providers and a 'survival guide' for substance users
Number of subjects: 0
Study 12196612 — intervention group
Group type: EXPERIMENTAL
Intervention: Training intervention for injection drug users to serve as peer mentors
Number of subjects: 0
Study 12196612 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational intervention for day care teaching staff on asthma awareness
Number of subjects: 0
Study 9385614 — intervention group
Group type: EXPERIMENTAL
Intervention: Clomipramine (12.5 mg, intravenous, single dose)
Number of subjects: 19
Study 9385614 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate weight loss in subjects with obesity
Number of subjects: 19
Study 9385614 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline plasma leptin concentrations
Number of subjects: 19
Study 7878638 — intervention group
Group type: EXPERIMENTAL
Intervention: Methacholine (Mch) infusion (0.1‐0.8‐4.0 micrograms/min)
Number of subjects: 7
Study 7878638 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium nitroprusside (SNP) infusion (0.5‐2.5‐10 micrograms/min)
Number of subjects: 7
Study 7878638 — intervention group
Group type: COMPARATOR
Intervention: Pre-infusion baseline
Number of subjects: 7
Study 3225660 — intervention group
Group type: EXPERIMENTAL
Intervention: Weaning at 1700 g
Number of subjects: 60
Study 3225660 — intervention group
Group type: COMPARATOR
Intervention: Weaning at 1800 g
Number of subjects: 60
Study 3225660 — intervention group
Group type: EXPERIMENTAL
Intervention: Weaning at 1700 g (birth weight ≤ 1000 g)
Number of subjects: 60
Study 2035313 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide 200 micrograms
Number of subjects: 33
Study 2035313 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide 800 micrograms
Number of subjects: 33
Study 1000139 — intervention group
Group type: EXPERIMENTAL
Intervention: Clozapine
Number of subjects: 0
Study 1000139 — intervention group
Group type: EXPERIMENTAL
Intervention: Perphenazine
Number of subjects: 0
Study 31584739 — intervention group
Group type: EXPERIMENTAL
Intervention: AZD9977 (50, 150, and 300 mg, twice daily for 8 days)
Number of subjects: 27
Study 31584739 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 27
Study 31584739 — intervention group
Group type: EXPERIMENTAL
Intervention: AZD9977
Number of subjects: 27
Study 28668251 — intervention group
Group type: EXPERIMENTAL
Intervention: Bicycle train intervention (daily cycling with study staff to and from school)
Number of subjects: 54
Study 26426609 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone call performed (Group A)
Number of subjects: 300
Study 26426609 — intervention group
Group type: COMPARATOR
Intervention: No telephone call (Group B)
Number of subjects: 300
Study 23616506 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole walnuts (85 g)
Number of subjects: 15
Study 23616506 — intervention group
Group type: EXPERIMENTAL
Intervention: Nut skins (5.6 g)
Number of subjects: 15
Study 23616506 — intervention group
Group type: EXPERIMENTAL
Intervention: Nut oil (51 g)
Number of subjects: 15
Study 23616506 — intervention group
Group type: COMPARATOR
Intervention: De-fatted nutmeat (34 g)
Number of subjects: 15
Study 21158885 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent photic stimulation (IPS)
Number of subjects: 30
Study 21158885 — intervention group
Group type: COMPARATOR
Intervention: Control treatment
Number of subjects: 30
Study 19619360 — intervention group
Group type: EXPERIMENTAL
Intervention: Personal Contact (PC) program
Number of subjects: 690
Study 19619360 — intervention group
Group type: EXPERIMENTAL
Intervention: Internet-based program (IT)
Number of subjects: 690
Study 17185301 — intervention group
Group type: EXPERIMENTAL
Intervention: BoNT‐A injections
Number of subjects: 40
Study 17185301 — intervention group
Group type: COMPARATOR
Intervention: Placebo injections
Number of subjects: 40
Study 15020604 — intervention group
Group type: COMPARATOR
Intervention: AAWD alone
Number of subjects: 260
Study 15020604 — intervention group
Group type: EXPERIMENTAL
Intervention: AAWD and ketoconazole (400 mg orally tid)
Number of subjects: 260
Study 15020604 — intervention group
Group type: EXPERIMENTAL
Intervention: AAWD and ketoconazole
Number of subjects: 260
Study 15020604 — intervention group
Group type: EXPERIMENTAL
Intervention: Deferred treatment with ketoconazole
Number of subjects: 260
Study 11278149 — intervention group
Group type: EXPERIMENTAL
Intervention: Physostigmine; specific dosage and duration not mentioned
Number of subjects: 0
Study 11278149 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified; no control intervention mentioned
Number of subjects: 0
Study 9727818 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenylpropanolamine (12.5 mg)
Number of subjects: 35
Study 9727818 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenylpropanolamine (25 mg)
Number of subjects: 35
Study 9727818 — intervention group
Group type: EXPERIMENTAL
Intervention: Yohimbine (5.4 mg)
Number of subjects: 35
Study 9727818 — intervention group
Group type: EXPERIMENTAL
Intervention: Indomethacin (50 mg)
Number of subjects: 35
Study 9727818 — intervention group
Group type: COMPARATOR
Intervention: Ibuprofen (600 mg)
Number of subjects: 35
Study 9727818 — intervention group
Group type: COMPARATOR
Intervention: Caffeine (250 mg)
Number of subjects: 35
Study 9727818 — intervention group
Group type: COMPARATOR
Intervention: Methylphenidate (5 mg)
Number of subjects: 35
Study 9727818 — intervention group
Group type: EXPERIMENTAL
Intervention: Midodrine (5 mg)
Number of subjects: 35
Study 8001526 — intervention group
Group type: EXPERIMENTAL
Intervention: Colour coded displays
Number of subjects: 0
Study 8001526 — intervention group
Group type: COMPARATOR
Intervention: Monochrome displays
Number of subjects: 0
Study 3175472 — intervention group
Group type: EXPERIMENTAL
Intervention: Ivermectin (150 or 200 micrograms/kg)
Number of subjects: 39
Study 31077667 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrogen (H2) dissolved in irrigation solution
Number of subjects: 32
Study 31077667 — intervention group
Group type: COMPARATOR
Intervention: Conventional solution (Control)
Number of subjects: 32
Study 28275066 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulsed Biphasic (PB) shocks
Number of subjects: 134
Study 28275066 — intervention group
Group type: COMPARATOR
Intervention: Biphasic Truncated Exponential (BTE) shocks
Number of subjects: 134
Study 28275066 — intervention group
Group type: EXPERIMENTAL
Intervention: Both PB and BTE shocks
Number of subjects: 134
Study 26008873 — intervention group
Group type: EXPERIMENTAL
Intervention: Partial weight‐supported treadmill training (PWSTT)
Number of subjects: 60
Study 26008873 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional gait training (CGT)
Number of subjects: 60
Study 26008873 — intervention group
Group type: COMPARATOR
Intervention: Nonexercising PD group
Number of subjects: 60
Study 24088965 — intervention group
Group type: EXPERIMENTAL
Intervention: Volar locking plate
Number of subjects: 130
Study 24088965 — intervention group
Group type: COMPARATOR
Intervention: Conventional percutaneous fixation
Number of subjects: 130
Study 22254118 — intervention group
Group type: EXPERIMENTAL
Intervention: Spirulina (19 g daily)
Number of subjects: 33
Study 22254118 — intervention group
Group type: COMPARATOR
Intervention: Soybean (19 g daily)
Number of subjects: 33
Study 19638081 — intervention group
Group type: EXPERIMENTAL
Intervention: Low residue test meals with 4L polyethylene glycol (TM-PEG 4L)
Number of subjects: 214
Study 19638081 — intervention group
Group type: COMPARATOR
Intervention: Clear liquid diet with 4L polyethylene glycol
Number of subjects: 214
Study 17045910 — intervention group
Group type: EXPERIMENTAL
Intervention: Granulocyte colony-stimulating factor (G-CSF)
Number of subjects: 44
Study 17045910 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 44
Study 14501380 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 microg selenized yeast
Number of subjects: 514
Study 14501380 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 microg selenized yeast
Number of subjects: 514
Study 14501380 — intervention group
Group type: COMPARATOR
Intervention: Matched placebo
Number of subjects: 514
Study 14501380 — intervention group
Group type: EXPERIMENTAL
Intervention: Selenized yeast (200 or 400 microg)
Number of subjects: 514
Study 10716539 — intervention group
Group type: EXPERIMENTAL
Intervention: Sibutramine 15 mg
Number of subjects: 24
Study 10716539 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 8785152 — intervention group
Group type: EXPERIMENTAL
Intervention: Bair-Hugger group (active skin surface warming with an upper body cover)
Number of subjects: 18
Study 8785152 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intraoperative warming device)
Number of subjects: 18
Study 8785152 — intervention group
Group type: EXPERIMENTAL
Intervention: Bair-Hugger group
Number of subjects: 18
Study 8785152 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 18
Study 1434338 — intervention group
Group type: EXPERIMENTAL
Intervention: Borage oil (Glandol)
Number of subjects: 12
Study 1434338 — intervention group
Group type: COMPARATOR
Intervention: Placebo (palm seed oil)
Number of subjects: 12
Study 3881125 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.1% betamethasone disodium phosphate
Number of subjects: 71
Study 3881125 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5% prednisolone disodium phosphate
Number of subjects: 71
Study 3881125 — intervention group
Group type: EXPERIMENTAL
Intervention: 5% tolmetin sodium dihydrate
Number of subjects: 71
Study 31478309 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse-driven targeted HIV screening with routine diagnostic testing
Number of subjects: 8
Study 29807890 — intervention group
Group type: EXPERIMENTAL
Intervention: CRT-ON
Number of subjects: 787
Study 29807890 — intervention group
Group type: COMPARATOR
Intervention: CRT-OFF
Number of subjects: 787
Study 27509222 — intervention group
Group type: EXPERIMENTAL
Intervention: Hemoglobin drop of at least 1g/dL
Number of subjects: 433
Study 27509222 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher hemoglobin concentrations by discharge
Number of subjects: 433
Study 27509222 — intervention group
Group type: COMPARATOR
Intervention: Pulmonary artery catheter (PAC) use
Number of subjects: 433
Study 27509222 — intervention group
Group type: EXPERIMENTAL
Intervention: Hospital length of stay
Number of subjects: 433
Study 25720616 — intervention group
Group type: EXPERIMENTAL
Intervention: Personal genetic information (apoE genotype-based health advice)
Number of subjects: 107
Study 25720616 — intervention group
Group type: COMPARATOR
Intervention: Control group (no personal genetic information)
Number of subjects: 107
Study 23665124 — intervention group
Group type: EXPERIMENTAL
Intervention: Local infiltration (150ml 0.2% ropivacaine/1ml 1:1000 adrenaline/30mg ketorolac)
Number of subjects: 40
Study 23665124 — intervention group
Group type: COMPARATOR
Intervention: Single shot femoral nerve block (30ml 0.2% ropivacaine)
Number of subjects: 40